Related references
Note: Only part of the references are listed.Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine
J. Sadoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Peter Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens
Jasper Fuk-Woo Chan et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2020)
Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS
Yushun Wan et al.
JOURNAL OF VIROLOGY (2020)
A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
Jasper Fuk-Woo Chan et al.
LANCET (2020)
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou et al.
NATURE (2020)
A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract
Yixuan J. Hou et al.
CELL (2020)
Identification of Human Single-Domain Antibodies against SARS-CoV-2
Yanling Wu et al.
CELL HOST & MICROBE (2020)
Surgical Mask Partition Reduces the Risk of Noncontact Transmission in a Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19)
Jasper Fuk-Woo Chan et al.
CLINICAL INFECTIOUS DISEASES (2020)
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
Jasper Fuk-Woo Chan et al.
EMERGING MICROBES & INFECTIONS (2020)
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Kai Duan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
Yan Wu et al.
SCIENCE (2020)
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Ivan Fan-Ngai Hung et al.
LANCET (2020)
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Rui Shi et al.
NATURE (2020)
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Jun Lan et al.
NATURE (2020)
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Jason D. Goldman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells
Yunlong Cao et al.
CELL (2020)
Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses
Runhong Zhou et al.
IMMUNITY (2020)
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials
Shengli Xia et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series
Ivan Fan-Ngai Hung et al.
LANCET INFECTIOUS DISEASES (2020)
Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?
Maria Dalamaga et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2020)
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Laura Riva et al.
NATURE (2020)
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Davide F. Robbiani et al.
NATURE (2020)
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Lihong Liu et al.
NATURE (2020)
Potently neutralizing and protective human antibodies against SARS-CoV-2
Seth J. Zost et al.
NATURE (2020)
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
David R. Boulware et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Xiangyang Chi et al.
SCIENCE (2020)
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Thomas F. Rogers et al.
SCIENCE (2020)
Structural basis of a shared antibody response to SARS-CoV-2
Meng Yuan et al.
SCIENCE (2020)
SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses
He-wei Jiang et al.
NATURE COMMUNICATIONS (2020)
Kinetics of viral load and antibody response in relation to COVID-19 severity
Yanqun Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Ugur Sahin et al.
NATURE (2020)
REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
Alina Baum et al.
SCIENCE (2020)
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
Mehul S. Suthar et al.
CELL REPORTS MEDICINE (2020)
Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study
Hin Chu et al.
LANCET MICROBE (2020)
Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold
Zehua Sun et al.
MABS (2020)
SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease
Pengfei Wang et al.
EMERGING MICROBES & INFECTIONS (2020)
High neutralizing antibody titer in intensive care unit patients with COVID-19
Li Liu et al.
EMERGING MICROBES & INFECTIONS (2020)
Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19
Pengcheng Liu et al.
EMERGING MICROBES & INFECTIONS (2020)
Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection
Li Liu et al.
JCI INSIGHT (2019)
Simian Immunodeficiency Virus Infection Evades Vaccine-Elicited Antibody Responses to V2 Region
Jia Guo et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
Comprehensive Analysis of Pathogen-specific Antibody Response in Vivo Based on an Antigen Library Displayed on Surface of Yeast
Teng Zuo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Isolating and engineering human antibodies using yeast surface display
Ginger Chao et al.
NATURE PROTOCOLS (2006)
Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain
CE Yi et al.
JOURNAL OF VIROLOGY (2005)
Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region
ZW Chen et al.
JOURNAL OF VIROLOGY (2005)
Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study
JSM Peiris et al.
LANCET (2003)
Share Paper
